ADMA Biologics (NASDAQ:ADMA) Given New $13.00 Price Target at Cantor Fitzgerald

ADMA Biologics (NASDAQ:ADMA) had its price objective boosted by analysts at Cantor Fitzgerald from $12.00 to $13.00 in a report released on Thursday, Benzinga reports. The firm currently has a “neutral” rating on the biotechnology company’s stock. Cantor Fitzgerald‘s price target points to a potential upside of 24.05% from the stock’s current price.

Several other analysts have also weighed in on the company. Weiss Ratings reissued a “hold (c)” rating on shares of ADMA Biologics in a report on Monday, September 14th. Zacks Research upgraded ADMA Biologics from a “strong sell” rating to a “hold” rating in a report on Wednesday, September 2nd. Finally, Mizuho set a $18.00 price target on ADMA Biologics in a research note on Thursday. Three investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, ADMA Biologics has a consensus rating of “Moderate Buy” and a consensus target price of $17.50.

ADMA Biologics Price Performance

ADMA Biologics stock opened at $10.48 on Thursday. The company has a fifty day simple moving average of $10.07 and a 200-day simple moving average of $10.93. The company has a current ratio of 6.97, a quick ratio of 3.81 and a debt-to-equity ratio of 0.49. The stock has a market cap of $2.35 billion, a P/E ratio of 14.97 and a beta of 0.65. ADMA Biologics has a 12-month low of $7.21 and a 12-month high of $20.46.

ADMA Biologics (NASDAQ:ADMA) last announced its earnings results on Wednesday, November 4th. The biotechnology company reported $0.23 EPS for the quarter, beating analysts’ consensus estimates of $0.20 by $0.03. The business had revenue of $141.10 million for the quarter, compared to analysts’ expectations of $138.11 million. ADMA Biologics had a net margin of 32.98% and a return on equity of 40.17%. The company’s quarterly revenue was up 5.1% on a year-over-year basis. During the same period in the previous year, the company posted $0.15 EPS. Equities analysts expect that ADMA Biologics will post 0.78 EPS for the current fiscal year.

Institutional Investors Weigh In On ADMA Biologics

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Lido Advisors LLC grew its position in shares of ADMA Biologics by 35.3% during the third quarter. Lido Advisors LLC now owns 32,699 shares of the biotechnology company’s stock worth $328,000 after buying an additional 8,525 shares in the last quarter. Fulcrum Asset Management LLP lifted its position in shares of ADMA Biologics by 1,306.3% during the third quarter. Fulcrum Asset Management LLP now owns 14,963 shares of the biotechnology company’s stock worth $149,000 after purchasing an additional 13,899 shares during the last quarter. Allspring Global Investments Holdings LLC grew its stake in ADMA Biologics by 4.3% in the third quarter. Allspring Global Investments Holdings LLC now owns 32,087 shares of the biotechnology company’s stock worth $319,000 after purchasing an additional 1,316 shares in the last quarter. Ethic Inc. acquired a new position in shares of ADMA Biologics in the 3rd quarter worth approximately $131,000. Finally, Alps Advisors Inc. raised its holdings in shares of ADMA Biologics by 91.5% during the third quarter. Alps Advisors Inc. now owns 63,495 shares of the biotechnology company’s stock worth $637,000 after purchasing an additional 30,331 shares during the period. 75.68% of the stock is currently owned by hedge funds and other institutional investors.

ADMA Biologics News Summary

Here are the key news stories impacting ADMA Biologics this week:

• Positive Sentiment: ADMA reported Q3 revenue of $141.1 million, up 5% year over year and above analyst estimates. GAAP EPS was $0.22 and adjusted EPS was $0.23, both ahead of consensus; net income and adjusted EBITDA also grew year over year. ADMA Biologics Q3 2026 results
• Positive Sentiment: ASCENIV revenue rose 31% to $124.7 million, while gross margin expanded to 71% from a year earlier—supporting the company’s growth and profitability story. ADMA Biologics Q3 2026 earnings
• Positive Sentiment: The company reiterated its 2026 revenue outlook of at least $530 million and raised its minimum adjusted EBITDA outlook to at least $275 million, citing accelerating ASCENIV demand. Higher expected earnings could support investor confidence. ADMA reiterates revenue outlook and raises EBITDA outlook
• Positive Sentiment: ADMA also cited encouraging FDA feedback on its SG-001 pre-IND package, alongside cash generation and share repurchases. These could offer additional support, though the pipeline program is earlier-stage. ADMA business update

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company focused on developing, manufacturing and commercializing plasma-derived biologic products for people with compromised or weakened immune systems. The company’s activities include collecting human plasma, developing immune globulin therapies and manufacturing products for use in the prevention and treatment of certain infectious diseases.

ADMA’s portfolio includes Asceniv, an intravenous immune globulin indicated for primary humoral immunodeficiency disease, and Bivigam, an intravenous immune globulin used for the treatment of primary humoral immunodeficiency.